4.5 Article

Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension

期刊

HYPERTENSION RESEARCH
卷 34, 期 4, 页码 509-515

出版社

SPRINGERNATURE
DOI: 10.1038/hr.2010.260

关键词

candesartan; fibrinolysis; imidapril; insulin sensitivity

向作者/读者索取更多资源

The aim of this study was to evaluate the effects of imidapril and candesartan on fibrinolysis and insulin sensitivity in normoweight hypertensive patients. After a 2-week wash-out period, 61 patients with mild-to-moderate hypertension were randomized to imidapril or candesartan for 12 weeks. Blood pressure (BP), plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) antigen activities were evaluated at baseline and during treatment. The patients underwent a euglycemic-hyperinsulinemic clamp (insulin sensitivity was evaluated as glucose infusion rate during the last 30 min) and a desmopressin test (with desmopressin infusion in the brachial artery) to evaluate endothelial ability to release t-PA. Imidapril and candesartan induced similar systolic/diastolic BP reductions (-16/12.6 and -16.1/12.2 mm Hg, respectively, P < 0.001 vs. baseline). Imidapril increased glucose infusion rate (+1.1 mg min(-1) per kg, P < 0.02), whereas candesartan did not change it. Both drugs decreased PAI-1 antigen activity after 4 weeks of treatment; subsequently, only the decreasing effect of imidapril was sustained throughout the 12 weeks, whereas candesartan increased PAI-1 activity at week 12 (P < 0.05 vs. baseline, P < 0.01 vs. imidapril). Activity of t-PA decreased with candesartan (from 0.48 +/- 0.16 to 0.43 +/- 0.14 IU ml(-1), P < 0.05) but not with imidapril. Activity of t-PA in response to desmopressin was increased more by imidapril (+4.45 IU ml(-1)) than by candesartan (+2.73 IU ml(-1), P < 0.01 vs. imidapril). These results indicate that in normoweight hypertensive patients, despite similar BP reduction, imidapril but not candesartan improved the fibrinolytic balance, suggesting that mechanisms other than Ang II inhibition, possibly including bradykinin-mediated effects on insulin sensitivity and endothelial function, may be responsible for these different effects. Hypertension Research (2011) 34, 509-515; doi:10.1038/hr.2010.260; published online 23 December 2010

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据